Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | MC3R | P41968 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28667072 | 0.83 | PCSK9 (0.39) | — | |
| SCHEMBL609052 | 0.79 | IRAK4 (0.32) | — | |
| SCHEMBL609051 | 0.79 | IRAK4 (0.32) | — | |
| SCHEMBL12200521 | 0.79 | IRAK4 (0.31) | — | |
| SCHEMBL12200518 | 0.79 | IRAK4 (0.31) | — | |
| SCHEMBL28668136 | 0.75 | — | — | |
| SCHEMBL1445670 | 0.75 | CNR2 (0.36) | — | |
| SCHEMBL1445671 | 0.75 | CNR2 (0.36) | — | |
| SCHEMBL589628 | 0.72 | FPR2 (0.43) | SIRT6ADRA1AFPR2SCN9A | |
| SCHEMBL27751224 | 0.72 | CA2 (0.47) | SIRT6FPR2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2274297-B1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2012-05-09 | — | — | EP | claimed |
| US-7741327-B2 | Pyrrolidinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2010-06-22 | — | — | US | claimed |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | claimed |
| US-8697705-B2 | Isoindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20130296339-A1 | ISOINDOLINONE DERIVATIVES | HOFFMANN LA ROCHE (US) | 2013-11-07 | — | — | US | disclosed |
| US-8470866-B2 | Isoindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120283271-A1 | ISOINDOLINONE DERIVATIVES | BERTHEL STEVEN JOSEPH (US) | 2012-11-08 | — | — | US | disclosed |
| EP-2274297-B1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2012-05-09 | — | — | EP | disclosed |
| US-7741327-B2 | Pyrrolidinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
| WO-2009127546-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283271-A1 | ISOINDOLINONE DERIVATIVES | GCK, GCKR, PDK2 | SIRT6 551/4885ADORA3 2437/4885TSHR 4028/4885 |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | GCKR, GCK, PDK2 | SIRT6 566/4885ADORA3 2616/4885TSHR 3084/4885 |
| US-20130296339-A1 | ISOINDOLINONE DERIVATIVES | GCK, GCKR, PDK2 | SIRT6 551/4885ADORA3 2437/4885TSHR 4028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.